Copertina

Role of immune checkpoint inhibitors combined with chemotherapy in recurrent drug‐resistant gestational trophoblastic neoplasia: Four case reports and literature review

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Weiqing Liu, Yukai Zhu, Ya Wang, Rong Li, Dongling Zou, Rui Chen, Lu Yang, Yu Huang
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Cancer Reports
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Inconsistency in steroid use as antiemetics in clinical trial protocols involving immune checkpoint inhibitors combined with chemotherapy
di: Soh Mee Park, et al.
Pubblicazione: (2024)

A dramatic response to an immune checkpoint inhibitor plus chemotherapy in a patient with metastatic metaplastic carcinoma of the breast: A case report
di: Yumiko Koi, et al.
Pubblicazione: (2024)

Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma
di: Xuemei Zhang, et al.
Pubblicazione: (2024)

Persist or resist: Immune checkpoint inhibitors in EGFR‐mutated NSCLC
di: Pengcheng Zhu, et al.
Pubblicazione: (2024)

The effect of common medications on the efficacy of immune checkpoint inhibitors
di: Daria Brinzevich, et al.
Pubblicazione: (2025)

Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta‐analysis
di: Shoutao Dang, et al.
Pubblicazione: (2024)

Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non‐small‐cell lung cancer
di: Ayako Morita, et al.
Pubblicazione: (2024)

Correction to “The effect of common medications on the efficacy of immune checkpoint inhibitors”
Pubblicazione: (2026)

Revisiting the impact of common medications on immune checkpoint inhibitor efficacy
di: Parham Habibzadeh, et al.
Pubblicazione: (2026)

Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor
di: Georges Gebrael, et al.
Pubblicazione: (2024)

Mechanism research of non‐coding RNA in immune checkpoint inhibitors therapy
di: Jie Bian, et al.
Pubblicazione: (2024)

Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer
di: Zhuo Cheng, et al.
Pubblicazione: (2024)

Efficacy and safety of novel immune checkpoint inhibitor‐based combinations versus chemotherapy as first‐line treatment for patients with extensive‐stage small cell lung cancer: A network meta‐analysis
di: Chuang Yang, et al.
Pubblicazione: (2024)

Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors
di: Yuan Meng, et al.
Pubblicazione: (2024)

Chemotherapy versus chemotherapy plus immune checkpoint inhibitors for the first‐line treatment of unresectable thymic carcinoma: A multicenter retrospective study
di: Baishen Zhang, et al.
Pubblicazione: (2024)

Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy
di: Michael Masetti, et al.
Pubblicazione: (2024)

Lymphocyte activation markers predict the therapeutic response to immune checkpoint inhibitors: A case–control study
di: Takuya Iwamoto, et al.
Pubblicazione: (2024)

Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer
di: Gen Lin, et al.
Pubblicazione: (2024)

Relationship between the combination of platelet count and neutrophil‐lymphocyte ratio and prognosis of patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study
di: Saeko Kashimura, et al.
Pubblicazione: (2024)

Interleukin‐4 induced 1‐mediated resistance to an immune checkpoint inhibitor through suppression of CD8+ T cell infiltration in melanoma
di: Shiho Hirose, et al.
Pubblicazione: (2024)

Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor
di: Hao Xiong, et al.
Pubblicazione: (2024)

Prognostic value of cardiovascular magnetic resonance in immune checkpoint inhibitor‐associated myocarditis: A systematic review and meta‐analysis
di: Wenhua Song, et al.
Pubblicazione: (2024)

Incidence and risk factors of immune‐related adverse events induced by immune checkpoint inhibitors among older adults with non‐small cell lung cancer
di: Yiran Rong, et al.
Pubblicazione: (2024)

Early identification of severe immune checkpoint inhibitor associated myocarditis: From an electrocardiographic perspective
di: Yongyin Gao, et al.
Pubblicazione: (2024)

Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor
di: Guiming Deng, et al.
Pubblicazione: (2024)

Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non‐small cell lung cancer
di: Jie Zhao, et al.
Pubblicazione: (2024)

Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study
di: Yi Zheng, et al.
Pubblicazione: (2024)

Blood‐based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy
di: Brie‐Anne Mannah, et al.
Pubblicazione: (2025)

Clinical implications of PD ‐ L1 expression in oncogene‐driven NSCLC : Differential responses to targeted agents and immune checkpoint inhibitors
di: Xiaoxiao Fan, et al.
Pubblicazione: (2026)

Immune checkpoint inhibitors increase the risk of psoriasis
di: Mary Beth Nierengarten
Pubblicazione: (2025)

Host ANGPTL2 establishes an immunosuppressive tumor microenvironment and resistance to immune checkpoint therapy
di: Shinsei Yumoto, et al.
Pubblicazione: (2024)

Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer
di: Shuling Shi, et al.
Pubblicazione: (2024)

Interpretable machine learning model predicting immune checkpoint inhibitor‐induced hypothyroidism: A retrospective cohort study
di: Su‐Yan Zhu, et al.
Pubblicazione: (2024)

Impact of immune checkpoint inhibitors on survival outcomes in advanced gastric cancer in Japan: A real‐world analysis
di: Toru Kadono, et al.
Pubblicazione: (2024)

Tumor mutation load better predicts the prognosis of patients treated with immune checkpoint inhibitors in upper gastrointestinal cancers: A systematic review and meta‐analysis
di: Chenghao Ma, et al.
Pubblicazione: (2024)

Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma
di: Angela E. Alnemri, et al.
Pubblicazione: (2024)

Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
di: Tadashi Nishimura, et al.
Pubblicazione: (2024)

Cyclin‐dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple‐negative breast cancer by affecting the immune microenvironment
di: Jiayi Wu, et al.
Pubblicazione: (2024)

Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer
di: Han Li, et al.
Pubblicazione: (2024)

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study
di: Haiqing Zhao, et al.
Pubblicazione: (2024)